PROMISE-UNIPA-HCC Group

Hepatocellular Carcinoma Group. Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties(PROMISE). University of Palermo

[Roberto Cannella @cannella_rob]

We just started our clinical and research activities with MR elastography in our MR 3T Philips Ingenia at the Policlinico P. Giaccone, University of Palermo!

A huge thank to our Gastroenterology Unit and especially to Prof. Petta for providing this technology @PROMISEUnipaHCC

[AISF - Associazione Italiana Studio Fegato @AisfFegato]

Il Dott. Giuseppe Cabibbo, ricercatore universitario, ci racconta i recenti successi dello Special Interest Group di AISF dedicato all'epatocarcinoma: dalla pubblicazione su The Lancet Oncology alle linee guida sull'epatocarcinoma dell'ISS
https://t.co/MK5A5WVkWC

[PROMISE-UNIPA-HCC Group @PROMISEUnipaHCC]

A new perspective on management of #HCC now online on @TheLancetOncol by HCC Special interest group of Italian Association for study of liver disease @AisfFegato @Vaital73 @cabibbo78 @FRPonziani @LaiQuirino @DJPinato @casadei_gardini @CiroCelsa @prof_cillo https://t.co/wMv05I2sKm

[Paolo Giuffrida @GiuffridaPaolo]

Good luck to the new @AisfFegato Secretary
Congratulations Prof.@Calvar1Vincenza
#promiseUNIPA @unipa_it

[Giuseppe Cabibbo @cabibbo78]

BCLC 2022 update. Discussing outcomes in advanced HCC with @bruixj @ma5RN @LorenzaRimassa Jordi Rimola and Roman Kloeckner

[PROMISE-UNIPA-HCC Group @PROMISEUnipaHCC]

#HCC Sicily network. The Sicilian #Gastroenterology school in Rome

[Federica Vernuccio @DrF_Vernuccio]

LI-RADS and HCV cured cirrhotic patients: which is the role of indeterminate observations?
👇
Presence of LR-3 and LR-4 observations increases HCC risk following HCV eradication
Read at
https://t.co/whnBcq7dyI
@LIRADS5 @MDPIOpenAccess @cannella_rob @PROMISEUnipaHCC @PalermoRadpa

[Paolo Giuffrida @GiuffridaPaolo]

Thank’s #EASL for the nice opportunity
Can’t wait to attend this EASL summer school
@EASLedu @PROMISEUnipaHCC @unipa_it

[Paolo Giuffrida @GiuffridaPaolo]

It’s time for Prof.@Calvar1Vincenza to join the @AisfFegato board committee.
#AISFmeeting

[Giuseppe Cabibbo @cabibbo78]

HCC Surveillance Improves Early Detection, Curative Treatment Receipt, and Survival in Patients with Cirrhosis: A Systematic Review and Meta-Analysis https://t.co/zQkbcZRSO9 @docamitgs @ma5RN @EASLnews @AASLDtweets @PROMISEUnipaHCC

[Paolo Giuffrida @GiuffridaPaolo]

Adjusting #BCLC staging system to the evolving landscape of #HCC A look to the future https://t.co/nBJiyLGKF1
@cabibbo78 @PROMISEUnipaHCC @AGA_Gastro

[AISF - Associazione Italiana Studio Fegato @AisfFegato]

Stay tuned... @cabibbo78 @LaiQuirino @AghemoAlessio @FRPonziani @MarioMasarone @MontagneseSara

[Giuseppe Cabibbo @cabibbo78]

The quest for precision oncology with immune checkpoint inhibitors and hepatocellular carcinoma https://t.co/SwoYQA4cdp @docamitgs @DJPinato
Is CRAFITY score a suitable tool for predicting prognosis of HCC patients treated with ICI?

[Giuseppe Cabibbo @cabibbo78]

Now online!
Liver Cancer - https://t.co/5gISD4ER27 @KargerPublisher @ma5RN @CiroCelsa @docamitgs @bruixj
How assess net health benefit in the systemic therapy for HCC?
What is the optimal strategy for sequencing systemic agents after first-line ICI-based treatments?

[Giacomo E. M. Rizzo @GiacomoEMRizzo]

#honored and #grateful to Dr.ssa Ilaria Tarantino e Dr. Mario Traina for letting me experience #EUSFNB during #immersivereality presentation at #SIED2021

#OLYMPUS #SIED #Endoscopy #future

[Vincenza Calvaruso @Calvar1Vincenza]

Agreement and disagreement on what defines liver decompensation. Great experience on Baveno VII consensus workshop. Thanks to all Panel 5 members and to all outstanding faculty. @BavenoVII @Calvar1Vincenza

[Paolo Giuffrida @GiuffridaPaolo]

-What defines clinical decompensation of cirrhosis? No agreements on jaundice and bacterial infections
-carvedilol is the preferred NSBB to prevent decompensation
Great to see Prof.@Calvar1Vincenza at @BavenoVII

[Annals of Hepatology (AoH) @AnnalsofHepatol]

Direct-acting antiviral agents and risk of Hepatocellular carcinoma: critical appraisal of the evidence https://t.co/HLmBYN04eQ

[Ciro Celsa @CiroCelsa]

Great pleasure to have been part of @UEGWeekLive at PGT virtual 2021 this morning, discussing on diagnostic work-up of liver nouldes with @NaultJc, @JordiRimola, Nathalie Ganne-Carriè and Giuliana Amaddeo @my_ueg @PROMISEUnipaHCC

[Paolo Giuffrida @GiuffridaPaolo]

Direct-acting antiviral agents and risk of Hepatocellular carcinoma: critical appraisal of the evidence https://t.co/xriRWEIZt3
@PROMISEUnipaHCC @cabibbo78 @CiroCelsa @GiacchettoMarco @rancatoregab